Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

38.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
Via Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
Via Benzinga
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Via Benzinga
12 Analysts Have This To Say About Ionis Pharmaceuticals
Via Benzinga
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
From Biogen Inc.
Via GlobeNewswire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
The Latest Analyst Ratings For Ionis Pharmaceuticals
Via Benzinga
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Via Benzinga
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Masters In Trading - Saturday, June 22
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
Via Talk Markets
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year. 
Via Benzinga
Exposures Product Safety
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS. 
Via Benzinga
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes. 
Via Benzinga
The Latest Analyst Ratings For Ionis Pharmaceuticals
Via Benzinga
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
From Biogen Inc.
Via GlobeNewswire
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
Via InvestorPlace
IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with... 
Via Benzinga
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.